News News

April 21, 2021 Sirnaomics’ Spin-Off RNAimmune Secures $10 Million Seed Financing to Advance its mRNA-Based Vaccine and Therapeutic Development

RNAimmune, Inc., a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, announced today…

April 18, 2021 Sirnaomics Initiates Phase 2 Study Using STP705 for Keloid Scar Prevention

Company Expects to Report Interim Clinical Data in the Second Half of 2021 Sirnaomics, Inc., a biopharmaceutical…

February 3, 2021 Sirnaomics to Present at Medical Dermatology Summit

Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and…

January 17, 2021 Sirnaomics Announces First Patient Dosed In Phase 2a Study of STP705 for Treatment of Cutaneous Basal Cell Carcinoma, Company Expects to Report Initial Clinical Data in 2021

Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and…

December 20, 2020 Sirnaomics Reports Positive Data from Phase 2a Study of STP705 for Treatment of Squamous Cell Skin Cancer

Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and…

December 3, 2020 Sirnaomics to Initiate Phase I Study of STP705 in Treatment of Primary and Metastatic Liver Cancer

Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and…

1 2 3 4 5 12